Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

Dimerix Ltd (ASX: DXB)

The Dimerix share price is up 3.5% to 57 cents. Investors have been buying this biopharmaceutical company's shares following the release of its quarterly update. Dimerix achieved cash receipts of $51 million for the quarter. This was driven by the signing of a license agreement for DMX-200 with Amicus Therapeutics in the United States. Looking ahead, management reminded investors that the agreement could see Dimerix receive up to US$590 million (~AU$940 million) in upfront, development, and sales milestone payments, plus royalties.

Newmont Corporation (ASX: NEM)

The Newmont share price is up over 3% to $94.98. This follows the release of the gold mining giant's second quarter update. Newmont posted net income of US$2.1 billion for the three months. Management notes that this means the company is on track to achieve its guidance for FY 2025. CEO Tom Palmer said: "Newmont delivered a strong second quarter, producing approximately 1.5 million attributable gold ounces and generating an all time record quarterly free cash flow of $1.7 billion, underscoring the strength of our world-class portfolio and the disciplined execution of the commitments we shared at the beginning of the year. We remain firmly on track to achieve our 2025 guidance as we continue to strengthen our safety culture, stabilize our operations and deliver long term value to shareholders."

Regal Partners Ltd (ASX: RPL)

The Regal Partners share price is up almost 4% to $2.76. This has been driven by the release of the fund manager's latest funds under management (FUM) update. For the three months ended 30 June, Regal Partners reported a 7% increase in FUM to $17.7 billion. Management notes that the increase in FUM was driven by a combination of continued net client inflows and positive investment performance across a wide range of investment strategies.

Titomic Ltd (ASX: TTT)

The Titomic share price is up 6.5% to 27.7 cents. This morning, the manufacturing company revealed that it has raised $50 million via a non-underwritten placement to new and existing institutional and sophisticated investors. These funds were raised a 25 cents per share, which represents a modest 3.8% discount to its last close price. Titomic's CEO, Jim Simpson, said: "We look forward to using the proceeds raised to accelerate Titomic's expansion, enabling the Company to sustain its momentum across key growth initiatives while reinforcing its global footprint."

The post Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

Dimerix Ltd (ASX: DXB)

The Dimerix share price is up 4% to 73 cents. This morning, this biopharmaceutical company announced that it has received the initial payment of US$30 million (A$48 million) relating to the license agreement with Amicus Therapeutics. Under the agreement, Amicus has been granted exclusive rights to commercialise DMX-200 for FSGS in the United States. But the payments may not stop there. Dimerix remains eligible for further potential development milestones of up to US$560 million (~A$892 million) for success-based milestone payments, in addition to tiered royalties on US sales.

Evolution Mining Ltd (ASX: EVN)

The Evolution Mining share price is up 6% to $8.59. Investors have been buying Evolution Mining shares today after the gold price charged higher overnight. This was driven by a weaker US dollar and safe haven demand. It isn't just Evolution Mining that is rising today. A good number of ASX gold mining shares are recording strong gains. As a result, the S&P/ASX All Ordinaries Gold index is up 4.6% at the time of writing.

Inghams Group Ltd (ASX: ING)

The Inghams share price is up almost 2.5% to $3.58. This follows the release of a trading update from the poultry producer this morning. According to the release, the company has reaffirmed its FY 2025 guidance for Core Poultry Volume growth of -1% to -3% and underlying EBITDA of $236 million to $250 million. Management also revealed that it has substantially covered (>92%), on an annualised basis, the total volume reduction under the new Woolworths supply agreement, with the new business commencing progressively during the second half of 2025.

Nextdc Ltd (ASX: NXT)

The Nextdc share price is up over 7% to $13.60. The catalyst for this has been the release of a trading update this morning from the data centre operator. NextDC revealed that after recent customer contract wins, its pro forma contracted utilisation at the end of March had increased by 52MW or 30% to 228MW since 31 December. NextDC CEO Craig Scroggie said: "We are very pleased to have recorded the largest increase in contracted utilisation in the Company's history. The rise of artificial intelligence and high-performance computing is reshaping the data centre industry at speed. Hyperscale customers are scaling AI-native infrastructure at unprecedented levels."

The post Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are storming higher:

Boss Energy Ltd (ASX: BOE)

The Boss Energy share price is up 6% to $3.60. Investors have been buying this uranium producer's shares this week following the release of its quarterly update. That update revealed that it has generated its first free cash flow from the Honeymoon Project in South Australia. Boss Energy's managing director, Duncan Craib, said: "This was a pivotal quarter for Boss as we started generating free cashflow at Honeymoon. This milestone is the result of the highly successful ramp up, which saw production and costs meet or exceed our guidance. Importantly, we generated robust margins at current prices, demonstrating the strength of Honeymoon in the current market and the project's immense upside on the back of future increases in the uranium price as the market tightens."

Capstone Copper Corp (ASX: CSC)

The Capstone Copper Corp share price is up 4% to $7.95. This follows the release of the copper miner's first quarter update. The company reported total copper production of 53,796 tonnes with a C1 cash costs of $2.59 per pound. This led to Capstone delivering record adjusted EBITDA of $179.9 million. This is more than double the $80.1 million it achieved for the first quarter of FY 2024. Capstone CEO, John MacKenzie, commented: "Our operations got off to a solid start in the first quarter, marked by record sulphide copper production from both Mantoverde and Mantos Blancos, as we achieved record revenues and EBITDA."

Dimerix Ltd (ASX: DXB)

The Dimerix share price is up a further 10% to 75 cents. Investors have been scrambling to buy this clinical-stage biopharmaceutical company's shares this week following some big news. Dimerix has entered into an exclusive U.S. licensing agreement with Amicus Therapeutics (NASDAQ: FOLD) for the commercialisation of its Phase 3 drug candidate DMX-200. The deal will see the company earn up to US$410 million (A$653 million) in commercial milestone payments, as well as a number of royalties and other milestone payments.

Platinum Asset Management Ltd (ASX: PTM)

The Platinum Asset Management share price is up a further 7% to 68 cents. This fund manager's shares have been racing higher this week after it confirmed that it is in early-stage merger talks with L1 Capital. It is a global investment firm. Platinum's CEO, Jeff Peters, said: "L1 Capital is a first-class manager with a strong investment track record. The Potential Merger provides an attractive opportunity to combine expertise and resources, and we will continue to explore if it's in the best interests of Platinum shareholders."

The post Why Boss Energy, Capstone, Dimerix, and Platinum shares are storming higher today appeared first on The Motley Fool Australia.

In morning trade, its shares are up a massive 58% to 76 cents thanks to some big news.

Which ASX All Ords stock is rocketing?

The stock in question is Dimerix Ltd (ASX: DXB), which is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases.

This morning, investors have been scrambling to buy its shares after it entered into an exclusive U.S. licensing agreement with Amicus Therapeutics (NASDAQ: FOLD) for the commercialisation of its Phase 3 drug candidate DMX-200.

DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal Phase 3 study, ACTION3, for the treatment of Focal Segmental Glomerulosclerosis (FSGS) kidney disease.

In early 2024, the ASX All Ords stock reported positive interim results from the ACTION3 trial in FSGS. It showed that DMX-200 was performing better than placebo in reducing proteinuria with no safety concerns to date. Full enrolment of ACTION3 is expected by year-end 2025.

Big money deal

According to the release, the deal will see Amicus Therapeutics gain exclusive rights to commercialise DMX-200 for all indications in the United States, while Dimerix retains the rights in other global markets.

As part of the agreement, the ASX All Ords stock will receive the following:

• US$30 million (~A$48 million) upfront.
• Up to US$75 million (~A$199 million) in milestone payments tied to Phase 3 trial success and regulatory approval.
• US$35 million (A$56 million) on first commercial sale in the U.S.
• Up to US$410 million (A$653 million) in commercial milestone payments.
• Tiered royalties on net sales in the U.S. ranging from low-teens to low-twenties.
• Up to US$40 million (A$64 million) for future indication milestones

Commenting on the news, the ASX All Ords stock's CEO and managing director, Dr Nina Webster, said:

We are delighted to partner with Amicus in the United States. The Amicus team has a remarkable history of successfully delivering rare disease medicines to those in need. Their expertise and resources will be crucial to help achieve our mutual objective of commercializing this innovative treatment.

I'm grateful to the dedicated Dimerix team, trial participants, and investigators for their continued commitment to developing a new therapy for patients with FSGS who currently have a poor prognosis and very limited treatment options.

Following today's gain, the Dimerix share price is now up almost 140% since this time last year.

The post Guess which ASX All Ords stock is rocketing 58% on big US news appeared first on The Motley Fool Australia.

In morning trade, the ASX healthcare stock is up 31% to 46.5 cents.

Why is this ASX healthcare stock rocketing?

Investors have been fighting to get hold of the clinical-stage biopharmaceutical company's shares after it released a very positive announcement.

According to the release, Dimerix has entered into an exclusive development and license agreement with FUSO Pharmaceutical Industries.

FUSO Pharmaceutical Industries is a Japan-based pharmaceutical company that is engaged in the development, manufacture, and sale of basic pharmaceutical products that are essential for medical treatment. This includes dialysis solutions for artificial kidneys, infusions and injections, and products related to infertility treatment.

The two parties have signed an agreement for the development and commercialisation of the ASX healthcare stock's phase 3 drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan.

FUSO will be responsible for all development costs, submissions, and maintenance of the regulatory dossier with the Japanese Pharmaceutical and Medical Device Agency (PMDA), as well as all sales and marketing activities in Japan.

This is the third license deal executed for DMX-200 following deals with Advanz Pharma and Taiba. Dimerix will retain all rights to commercialise DMX-200 in all territories other than those covered by these license agreements.

What is DMX-200?

DMX-200 is currently in global phase 3 clinical development for treatment of FSGS kidney disease, with a blinded interim analysis anticipated in August.

If successfully developed, it could be a very lucrative product for the ASX healthcare stock.

As part of the agreement with FUSO Pharmaceutical Industries, Dimerix will receive a payment of 300 million yen (~A$3.1 million) within 40 days of executing the agreement, 400 million yen (~A$4.1 million) on initiation of the first clinical trial site (anticipated in Q1 2025), plus potential development and commercialisation milestones of up to 9.8 billion yen (~A$100 million).

Commenting on the agreement, the ASX healthcare stock's CEO and managing director, Dr Nina Webster, said:

We are delighted to partner with FUSO for the commercialisation of DMX-200 in Japan. FUSO brings a wealth of experience in pharmaceutical development and sales and marketing across Japan, and with a proven record in sales and marketing products for patients with renal disease.

This partnership reflects a confidence not only in the significant potential for DMX-200 in FSGS patients but also in Dimerix' capabilities in the development of DMX-200. FUSO's expertise and resources will be invaluable in supporting Dimerix to advance our shared goal of developing and commercialising DMX-200 and bringing hope to those patients desperately in need of treatment options.

The post Guess which ASX healthcare stock is up 31% on big news appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are storming higher:

Dimerix Ltd (ASX: DXB)

The Dimerix share price is up almost 4% to 40.5 cents. This follows the release of a trial update from the biopharmaceutical company this morning. Dimerix advised that the first clinical site specialising in paediatric kidney disease was activated today in Mexico. This now allows for the active recruitment of adolescent patients into the ACTION3 Phase 3 clinical trial. This study is testing the efficacy and safety of DMX200 in patients with Focal Segmental Glomerulosclerosis (FSGS) kidney disease. This means that its recruitment remains on-track and its interim analysis is still currently expected around mid-2025.

Paladin Energy Ltd (ASX: PDN)

The Paladin Energy share price is up 11% to $9.96. Investors have been scrambling to buy Paladin Energy and other ASX uranium stocks today thanks to some big industry news. According to Reuters, Russian President Vladimir Putin has said that Moscow should consider limiting exports of uranium, titanium, and nickel in retaliation for Western sanctions. ASX nickel shares are also rising on the news on Thursday.

Pilbara Minerals Ltd (ASX: PLS)

The Pilbara Minerals share price is up a further 7% to $2.86. Lithium stocks are surging for a second day in a row amid reports that Chinese battery giant CATL has suspended production at two of its lepidolite lithium mines. The market appears to be treating this as a sign that lithium prices have now bottomed and are flooding back into the beaten down industry. Today's gain means that Pilbara Minerals' shares are now up a whopping 22% over the past two trading sessions.

Resolute Mining Ltd (ASX: RSG)

The Resolute Mining share price is up 4% to 66.7 cents. This follows the release of an exploration update from the gold miner this morning. Resolute CEO, Terry Holohan, commented: "We are progressing well with our priority of extending the life of the Mako operation with further drilling success and a significant increase in the Mineral Resources at the Tomboronkoto project which is close to the Mako processing facility. Engineering work is progressing in parallel to ensure an investment decision can be made on this project in early 2025."

The post Why Dimerix, Paladin Energy, Pilbara Minerals, and Resolute Mining shares are storming higher today appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Dimerix Ltd (ASX: DXB)

The Dimerix share price is down 7.5% to 37.5 cents. This is despite the release of a positive announcement out of the biopharmaceutical company this morning. According to the release, the first patient has successfully completed the ACTION3 Phase 3 clinical trial and has chosen to enter the global open-label extension (OLE) study. The OLE study is optional for all qualifying patients who have completed the ACTION3 Phase 3 clinical trial. It offers a 2-year treatment with DMX-200, which is being trialled as a potential treatment to address the significant unmet need of patients with focal segmental glomerulosclerosis.

Life360 Inc (ASX: 360)

The Life360 share price is down 6% to $17.45. This follows a sharp pullback in the location technology company's NASDAQ listed shares overnight. The catalyst for that decline appears to have been news of some heavy insider selling. According to the release, Life360's independent non-executive director, James Synge, sold a total of approximately 100,000 Life360 shares for an average of ~US$37.36. This equates to a total consideration of approximately US$3.7 million. Synge was a very early investor in Life360, having first invested more than 10 years ago in a private equity capacity.

S2 Resources Ltd (ASX: S2R)

The S2 Resources share price is down 7.5% to 8.6 cents. This may have been driven by a broker note out of Bell Potter this morning. According to the note, the broker has downgraded this gold explorer's shares to a speculative hold rating with a 10 cents price target (from 24 cents). In response to its drilling results, Bell Potter said: "The Greater Fosterville Project remains S2R's most advanced gold exploration project. Limited initial results at the first prospect drilled have returned economic grades and widths, but not sufficient data to define the scale of the opportunity."

SG Fleet Group Ltd (ASX: SGF)

The SG Fleet share price is down 10% to $2.63. This has been caused by the fleet management company's shares going ex-dividend this morning for its final dividend of FY 2024. Last month, the company declared a mammoth fully franked final and special dividend totalling 24.3 cents per share. This was the equivalent of an 8.4% dividend yield based on yesterday's close price. Eligible shareholders can look forward to receiving this payout on 25 September.

The post Why Dimerix, Life360, S2 Resources, and SG Fleet shares are sinking today appeared first on The Motley Fool Australia.

Let's review the top 10.

Top 10 most traded ASX shares in June

Here are the top 10 most traded ASX shares in June by volume (thus incorporating both buy and sell orders), according to Selfwealth Ltd (ASX: SWF).

We have also included the percentage of buy orders next to each ASX share.

Which ASX shares attracted the most buyer interest?

As you can see, ASX 200 mining giant Fortescue received the most buy orders among the top 10 shares.

The Fortescue share price tumbled 13.46% during the month of June. Perhaps investors saw greater value in the stock as the price declined.

Fortescue shares are now trading on a price-to-earnings (P/E) ratio of 7.92x. The Fortescue share price closed on Friday at a nine-month low of $22.10.

Top broker Goldman Sachs has a sell rating on Fortescue with a 12-month share price target of $16.20. But Michael Gable from Fairmont Equities says Fortescue shares are a buy.

BHP shares had the second strongest buying activity during the month.

The BHP share price closed on Friday at $43.40. Goldman has a buy rating on BHP with a 12-month price target of $48.40.

The iron ore price has been falling, and one major bank forecasts that the commodity will weaken further over the next year or so.

On Friday, the S&P/ASX 200 Index (ASX: XJO) closed at 7,959.3 points. It reached a new record high during intraday trading at 7,969.1. This was driven by news out of the US that inflation is easing.

The S&P/ASX All Ordinaries Index (ASX: XAO) closed at 8,206.1 points. The All Ords also set a new record high during intraday trading at 8,212.6 points.

Top 10 most traded US stocks in June

Here are the top 10 most traded US stocks in June among SelfWealth traders.

As shown, the quintessential artificial intelligence stock NVIDIA had the highest percentage of buy orders among the top 10 US shares.

The post Top 10 most traded ASX shares and US stocks in June appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Dimerix Ltd (ASX: DXB)

The Dimerix share price is down 4% to 45 cents. This is despite the release of an update from the biopharmaceutical company this morning. It advised that the independent data monitoring committee has confirmed the dose of DMX-200 to be used in adolescent patients aged 12-17 years participating in the ACTION3 clinical trial. This trial is for patients with focal segmental glomerulosclerosis (FSGS). Dimerix's Chief Medical Officer, Dr David Fuller, said: "This is especially important as paediatric FSGS remains an area of high unmet need with limited therapeutic options and a high risk of progression to end-stage kidney disease."

New Hope Corporation Ltd (ASX: NHC)

The New Hope share price is down 4% to $5.06. This follows news that the coal miner has raised $300 million via a convertible notes offering. The initial conversion price of the notes is $6.63 per share, which represents a conversion premium of 30% over the reference share price. New Hope's CEO, Rob Bishop, commented: "The capital provided by this global investor base at favourable terms will be instrumental to our pursuit of initiatives that are consistent with our strategy to maximise shareholder returns."

Pro Medicus Limited (ASX: PME)

The Pro Medicus share price is down 4% to $130.86. This may have been driven by profit taking after very strong gains from the health imaging technology company's shares in the last financial year. In addition, this morning Citi retained its sell rating on the company's shares but lifted its price target from $80.00 to $95.00. While the broker is forecasting very strong growth, it feels that Pro Medicus' share price indicates that even stronger growth is expected by the market.

West African Resources Ltd (ASX: WAF)

The West African Resources share price is down 13% to $1.38. This morning, this gold miner announced that it has received firm commitments from institutional and sophisticated investors for a placement. It is raising $150 million through the issue of 109.5 million new shares at a discount of $1.37 per new share. Management notes that there was strong support from both domestic and offshore institutions for the placement. The proceeds will support development activities at the Kiaka Gold Project.

The post Why Dimerix, New Hope, Pro Medicus, and West African Resources shares are sinking today appeared first on The Motley Fool Australia.

Me too!

The stock in question is clinical stage drug discovery and development company Dimerix Ltd (ASX: DXB)

As you can likely guess by the phenomenal share price growth, shown in the chart below, a lot's been going right with the company's drug development and discoveries.

Yep, just one year ago, you could have bought the ASX healthcare stock for 6.0 cents a share.

At market close on Thursday, shares finished trading up 9.91%, swapping hands for 61 cents apiece.

That's enough to turn a $5,000 investment into a whopping $50,833 in just 12 months.

Take that inflation!

Here's why investors have been sending the stock through the roof.

How has the ASX healthcare stock rocketed 858% in a year?

As mentioned up top, Dimerix has released numerous promising updates on its operations and product line over the year.

One of the biggest share price moving pieces of news was released on 5 October.

Investors sent the ASX healthcare stock rocketing 154.1% higher in a single day after the company, together with Advanz Pharma, reported it had entered into an exclusive license agreement for the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand for the commercialisation of its phase 3 drug candidate DMX-200.

DMX-200 is intended to treat focal segmental glomerulosclerosis kidney disease.

Also likely boosting investor sentiment in the ASX healthcare stock was the fact that Dimerix retained all rights to commercialise DMX-200 outside of these territories.

"We are excited to announce this partnership with Dimerix, which is fully in line with our strategy to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia," Advanz Pharma CEO Steffen Wagner said on the day.

The good times kept coming

As mentioned, Dimerix shares kept on gaining as the company released a series of other positive announcements over the following months.

Most recently, on 27 May, the ASX healthcare stock closed up 25.0% after reporting that Taiba Middle East had acquired exclusive rights to register and commercialise DMX-200 in the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, Bahrain and Iraq.

Atop the deal inked with Advanz Pharma, the two license deals provide almost $11.5 million in upfront payments to the ASX healthcare stock along with some $340 million in potential milestone payments.

"We are thrilled to partner with Dimerix in launching DMX-200 in the Middle East pending FDA approval," Taiba CEO Saif Al Hasani said.

The post If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now! appeared first on The Motley Fool Australia.

You're not alone!

The S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company has been going from strength to strength lately.

Just in the past few weeks, Telix made several announcements that sent the stock soaring.

First it announced positive results from its ProstACT SELECT clinical cancer trial. And just days later it reported on progress on approval for TLX250-CDx, its kidney cancer imaging agent, with the United States Food and Drug Administration (FDA).

So, just how well have shareholders in this ASX biotech share been faring?

Well, if you'd bought Telix shares one month ago you'd be sitting on a gain of 20% today.

If you'd bought at the start of 2024, you'd be up 78%.

And if you'd snapped up the ASX biotech share for a bargain $1.05 a share five years ago, you'd have watched those shares surge 1,606%.

Or enough to turn a $5,000 investment into $85,300!

Which bring us to Rory Hunter, portfolio manager of SG Hiscock's Medical Technology Fund.

The ASX biotech shares that could mimic Telix's success

The SG Hiscock's Medical Technology Fund will have done well with its Telix Pharmaceuticals holdings.

According to Hunter (courtesy of The Australian Financial Review):

We originally took a position [in Telix] back in 2019 and chief executive Christian Behrenbruch has delivered on all stated commercial milestones in a timely manner, which is a feat not often achieved among early stage biotechs.

Hunter remains moderately bullish on the outlook for the ASX biotech share. But he noted that in the case of this ASX biotech share, "The easy money has been made."

And he cautioned that "investors will need to stomach some volatility" with the Telix share price moving forward.

Though, as you can see on the price chart up top, that's something long-term shareholders in this ASX biotech share should already be well-familiar with.

When asked which stocks his fund holds that have the same explosive potential as Telix or Neuren Pharmaceuticals Ltd (ASX: NEU), Hunter pointed to Clarity Pharmaceuticals Ltd (ASX: CU6) and Dimerix Ltd (ASX: DXB).

He noted that Clarity Pharmaceuticals could replicate "Telix's success in radiotheranostics". While Dimerix could replicate "Neuren's success in rare diseases".

He added that with "assets in late-stage development", Dimerix was a potential M&A target.

Clarity, Hunter added, could also become a potential takeover target for its "exciting and compelling early-stage data".

The Clarity share price is already up a whopping 575% over 12 months.

The Dimerix share price has run even hotter. The ASX biotech share is up 817% over 12 months.

The post 2 ASX biotech shares that could be the next Telix Pharmaceuticals appeared first on The Motley Fool Australia.

In morning trade, the ASX healthcare stock is up 20% to a 52-week high of 36 cents.

Why is this ASX healthcare stock jumping?

The catalyst for this rise has been the successful completion of an institutional placement.

According to the release, Dimerix has received firm commitments to raise $20 million from a significant number of new and existing institutional and sophisticated investors.

Demand was so strong for the placement that the ASX healthcare stock was able to raise the funds at 30 cents per new share. This means that no discount was necessary for the institutional placement.

It also represents a premium of 29.2% to its 30-day volume weighted average price (VWAP) of 23.2 cents and a premium of 14.5% to the five-day VWAP of 26.2 cents.

Why was demand so strong?

The ASX healthcare stock's placement was in demand because it coincided with news from the ACTION3 Phase 3 trial.

The trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) was successful in the pre-specified interim analysis of the proteinuria (efficacy) endpoint from its first 72 randomised patients.

Management also highlights that analysis indicated that, using a statistical measure, DMX-200 is performing better than placebo in terms of reducing proteinuria (a surrogate marker of kidney disease progression) in patients with FSGS.

The company's CEO, Dr Nina Webster, commented:

We are delighted to welcome our new Institutional and sophisticated investors, and we appreciate the strong support from existing shareholders. This Placement was highly strategic as it provides sufficient funds to take Dimerix through the 2nd interim analysis and, including eligible R&D rebates, the completion of the ACTION3 Phase 3 clinical trial.

If the next interim analysis is compelling, the Company could seek to apply for accelerated marketing approval in certain jurisdictions. By completing this Placement, Dimerix has not only accessed funding from high quality institutional investors to deliver on its Phase 3 program, but also significantly strengthened its balance sheet and this puts us in a strong negotiating position with potential partners, particularly on the back of our successful interim analysis just announced.

The post Guess which ASX healthcare stock is rocketing 20% today appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:

Dimerix Ltd (ASX: DXB)

The Dimerix share price is up 20% to 18.5 cents. Investors have been buying this clinical-stage biopharmaceutical company's shares this week after it announced a licensing agreement with Advanz Pharma that could be worth up to ~$230 million. The agreement is for Dimerix's phase 3 drug candidate, DMX-200, for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease.

Evolution Mining Ltd (ASX: EVN)

The Evolution Mining share price is up 2% to $3.32. This is despite there being no news out of the gold miner. Investors appear to have been buying Evolution and other ASX gold shares today on the belief that they have been oversold in recent weeks.

GQG Partners Inc (ASX: GQG)

The GQG Partners share price is up 3% to $1.36. This has been driven by the release of the fund manager's latest funds under management (FUM) update. While GQG reported a 1.5% monthly decline in FUM for September, this compares favourably to a 3.5% decline by the ASX 200 index during the period.

Steadfast Group Ltd (ASX: SDF)

The Steadfast share price is up 1.5% to $5.58. Investors have been buying this insurance brokerage company's shares after it announced an acquisition. Steadfast is paying US$55 million to acquire ISU Group. It is one of the largest privately owned independent insurance agency networks in the United States of America. The deal is expected to be earnings per share accretive from the date of acquisition.

The post Why Dimerix, Evolution, GQG, and Steadfast shares are climbing today appeared first on The Motley Fool Australia.

So much so, at one stage today, the ASX healthcare share was up a further 48% to a 52-week high of 23 cents.

When Dimerix's shares reached that level, it meant they were up a mind-boggling 280% in the space of just two days.

The clinical-stage biopharmaceutical company's shares have pulled back a touch since hitting that high, but remain up 25% to 19.5 cents currently.

Why is this ASX healthcare share rocketing?

Investors have been scrambling to buy Dimerix's shares this week after it announced a licensing agreement with Advanz Pharma that could be worth up to ~$230 million.

The agreement is for its phase 3 drug candidate, DMX-200, for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease.

FSGS is a rare disease that causes kidney scarring and can lead to end-stage kidney disease. DMX-200's trials to date have been very promising and the first analysis outcome from its phase 3 trial is expected in March 2024.

This licensing agreement with Advanz Pharma, which covers DMX-200 in Australia, Canada, Europe, and New Zealand, would clearly be a big deal for the company. With a market capitalisation of approximately $80 million, it could generate revenue almost three times greater than its current valuation.

However, it does have to gain approval from regulators before that happens. It is also worth noting that the ~$230 million deal is predominantly based on unspecified milestones. So, it is unclear what will need to be achieved for the company to receive these funds.

Nevertheless, this is great news for the ASX healthcare share and shareholders will no doubt be eagerly awaiting an update on DMX-200 in March.

The post This ASX healthcare share has jumped 280% in just two days! appeared first on The Motley Fool Australia.

In morning trade, the ASX healthcare share was up a massive 130% to 14 cents.

It has since pulled back but remains up an impressive 89% to 11.5 cents at the time of writing.

Why is this ASX healthcare share rocketing?

Investors have been buying Dimerix shares today after the company announced licensing agreements for its DMX-200 product in Australia, Canada, Europe, and New Zealand.

DMX-200 is the company's phase 3 drug candidate for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It is a rare disease that causes kidney scarring and can lead to end-stage kidney disease. The first analysis outcome from its phase 3 trial is expected in March 2024.

According to the release, the licensing agreement with Advanz Pharma could be worth up to ~$230 million in upfront and milestone payments, plus royalties. The upfront component is $10.8 million potential milestone payments of up to $219 million. The balance will be paid in tiered royalties on net sales.

The release notes that Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and commercial platform to register and effectively promote the product and offer greater patient access. Dimerix retains all rights to commercialise DMX-200 outside of the agreed territories.

The ASX healthcare share's CEO, Dr Nina Webster, said:

We are delighted to be partnering with ADVANZ in Europe, UK, Australia, New Zealand and Canada. The ADVANZ team has a proven record in developing and commercialising medicines in areas with no approved therapies and high unmet needs. ADVANZ's expertise and resources will be invaluable in supporting Dimerix to advance our shared goal of commercialising this novel treatment, and this partnership recognises the decade of work by our dedicated team, consultants, trial participants, and investigators in the developing a new therapy for patients with FSGS.

The post Guess which ASX healthcare share is rocketing 130% on some big news appeared first on The Motley Fool Australia.

That's an approximate 4% gain for the biopharmaceutical company today after it released a key update regarding its CLARITY 2.0 clinical trial regarding COVID-19.

Here are the details.

Dimerix Phase 3 COVID-19 study to expand into Australia

Dimerix advised that it has entered into an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand its CLARITY 2.0 study.

It's not uncommon to see large studies be conducted across different jurisdictions, as it enables a wider testing sample for more robust outcomes.

For instance, researchers can gauge results across a number of demographics, ethnicities, age groups, and locations in various countries to understand any inter-human variables in how a drug might work.

Dimerix's seamless feasibility/phase 3 clinical trial, which is examining the effect of the company's DMX-200 drug candidate in COVID-19 patients with respiratory complications, will commence recruitment of 600 patients across six sites in NSW, VIC and QLD upon regulatory approval.

Currently, the study is "already approved and open for recruitment in India", and is being led by Professor Meg Jardine, Director of the NHMRC Clinical Trials Centre.

If successful, the company claims that DMX-200 "would likely be effective against the different Covid-19 strain mutations based on its mechanism of action".

As border restrictions begin to ease and lockdown mandates begin to wind back in the coming months, active COVID-19 cases and hospitalisations are expected to rise, as has been the case in other countries when doing so.

The release notes that "it is anticipated that a significant portion of the population will remain susceptible to Covid-19 because they are not vaccinated or do not get an adequate protective response from the vaccines".

This, it claims, is a driving factor for the need for COVID-19 treatments – like DMX-200 – on top of vaccines within Australia.

What's next for Dimerix?

To fund the Australian arm of the CLARITY 2.0 study, Dimerix's balance sheet is the "strongest it has been in the company's history" after it received $24 million from a recent share purchase and placement plan.

It will use this cash to finance the suite of clinical programs surrounding DMX-200 and progress the company's other candidate program, DMX-700, towards development.

The former also includes a phase 3 trial for a rare kidney disorder known as FSGS, whilst the DMX-700 program is centred on chronic obstructive pulmonary disorder (COPD).

Today's gains are a welcomed reprieve for shareholders, having endured a 5% loss over the month in their Dimerix holdings.

Dimerix share price snapshot

The Dimerix share price has climbed 21% this year to date, ahead of many of its biopharmaceutical peers.

Despite this, it has only gained 5.5% in the past 12 months, well behind the S&P/ASX 200 index (ASX: XJO)'s return of around 18% in that time.

The post Dimerix (ASX:DXB) share price jumps on COVID study update appeared first on The Motley Fool Australia.

At the meeting, CEO Dr Nina Webster looked back on a year she described as "pivotal for the future of Dimerix".

Webster also stated she expects the drug discovery company will begin to glide through the final stages of development and towards profitability.

While Webster's comments weren't released to the public until mid-afternoon, the Dimerix share price has been soaring since this morning.

At market close on Monday, shares in the company finished at 33 cents apiece. That represents a 6.45% gain on their previous closing price.

Let's take a look at the year that's been for Dimerix and what Webster believes the future will hold.

Dimerix's boss on a successful FY21

The Dimerix share price is in the green today, the same day the company presented its AGM.  

In the meeting, Webster pointed to the achievements the company made over financial year 2021.

These included 2 clinical studies in which the company's lead drug candidate, DMX-200, treated COVID-19 patients.

The company also prepared for another phase 3 study into using DMX-200 to treat focal segmental glomerulosclerosis (FSGS).

With numerous drugs in the final stage of trials, Webster noted the company's portfolio is positioned for growth with commercial potential.

Webster also noted that, while much of the global population is, or soon will be, vaccinated against COVID-19, there will still be a need for treatments against the virus.

Additionally, drugs that can treat severe COVID-19 have typically been more expensive than other similar drugs. This has provided DMX-200 with an attractive market.

Finally, Dimerix finished FY21 under budget.

The company is now looking forward to providing guidance for all its near-term propositions, including the FSGS phase 3 program and its 2 COVID-19 clinical studies.

Dimerix is also engaging with potential licensing partners with the aim to provide the best outcome for its patients and shareholders.

It's also building alliances with others in commercial, clinical and manufacturing areas to enhance its chances for success.

Dimerix share price snapshot

Today's included, the Dimerix share price has gained 35% so far this year.

It is also 30% higher than it was this time last year.

The post Dimerix (ASX:DXB) share price soars as boss looks back on 'pivotal' year appeared first on The Motley Fool Australia.

The S&P/ASX 200 index (ASX: XJO) has clipped 0.37% lower today and sits at 7,343 points, whereas the S&P/ASX 200 Health Care index (XHJ) has dropped around 1% from the open.

Yet, these 3 ASX healthcare shares are soaring well ahead of their benchmarks today. Let's take a closer look.

Neuroscientific Biopharmaceuticals Ltd (ASX: NSB)

Neuroscientific is concerned with the development of diagnostics and therapeutics for neurodegenerative diseases.

In today's trading, Neuroscientific's shares are changing hands at 48.5 cents each, which is a 10% gain from the open.

Two recent advancements made on the company's EmtinB drug label appear to have shot the company's shares to new highs. Neuro' is developing EmtinB as a treatment for all kinds of neurodegenerative conditions, such as Alzheimer's and MS.

On 31 August, Neuro' had positive data readouts from a pre-clinical study that showed EmtinB's potential "as an effective treatment for Multiple Sclerosis (MS)". The results add to a list of data that points to it being a potential MS drug candidate.

Aside from this, on 3 September the company advised it had received approval from AusIndustry under the R&D tax incentive program to develop EmtimB as a "novel therapeutic treatment for ocular conditions" with (up to) $25 million in rebates.

Bionomics Ltd (ASX: BNO)

Bionomics shares are now changing hands at 17.5 cents each, which is a 6% gain in afternoon trade. At one point today, shares in the biopharma company were trading at over 18 cents each, up 10% from the previous close.

A recent announcement concerning the company's lead clinical compound, BNC210, appears to have spurred on recent gains for Bionomics.

Last week it announced a "planned (the) commencement" of a clinical trial for BNC210, further investigating its use in the "acute treatment" of social anxiety disorder.

The compound had previously shown promising signs in a Phase 2a clinical study, where it produced "significant anti-anxiety signals".

It is recruiting 150 patients in the US-based study, and intends to submit an application "by the end of this year".

Investors continue to push this ASX healthcare share into the green as we finish trading this week.

Dimerix Ltd (ASX: DXB)

Shares in clinical biopharma company Dimerix hit an intraday high of 31 cents at one point today, an 11% gain from the previous close.

They have since cooled off slightly in afternoon trade and now trade at 30 cents each. Dimerix shares have been on the move today since the company made a key announcement earlier.

The company advised it had been given the green light in India to start the "feasibility/Phase 3 clinical study" of its lead drug candidate, DMX-200.

DMX-200 will now be investigated in the "treatment of respiratory complications associated with COVID-19 imminently", after the Indian authorities met on 2 September to discuss the study.

This marks the "final regulatory agency approval required" to commence the phase 3 study, known as CLARITY 2.0. The first patient is "expected to be dosed in the next few weeks".

Aside from this, DMX-200 is also being investigated in a Phase 3 clinical study for a rare set of kidney disorders.

These 3 ASX healthcare shares have stepped ahead of the broad indices in afternoon trade on Friday.

The post These 3 ASX Healthcare shares have soared over 10% today appeared first on The Motley Fool Australia.

Below we take a look at the clinical-stage biopharmaceutical company's announcement on COVID-19 treatment that looks to be driving investor interest.

What COVID-19 announcement did Dimerix make?

The Dimerix share price is rocketing after the company reported that Indian regulatory agency – the Central Drugs Standard Control Organization (DCGI) – has formally recommended approval of the DMX-200 clinical study in COVID-19 patients.

DMX-200 is Dimerix's lead drug candidate, developed to potentially treat focal segmental glomerulosclerosis (FSGS), respiratory problems relating to COVID-19, and diabetic kidney disease.

According to the release, numerous clinical sites in India are ready to start recruitment in the feasibility/Phase 3 clinical study of DMX-200 to treat COVID-related respiratory complications.

The DCGI regulatory approval was the final one required before launching the CLARITY 2.0 study. Dimerix expects the first of what may be 600 participants to be dosed inside the next few weeks. The company is still awaiting receipt of the approval permit to move forward.

What did management say?

Commenting on the progress, Dimerix's CEO Nina Webster said:

We are extremely pleased to be in a position to potentially treat COVID-19 patients suffering debilitating respiratory complications, through both the CLARITY 2.0 study as well as the REMAP-CAP study currently recruiting in Europe…

[I]f DMX-200 does show benefit in respiratory complications associated with COVID-19, it may also show benefit in respiratory complications associated with other infections too, such as pneumonia and influenza. Thus, this provides an opportunity that could extend well beyond the impact of COVID-19.

The study is being led by Professor Meg Jardine, director of the NHMRC Clinical Trials Centre at The University of Sydney, along with Professor Vivek Jha and The George Institute for Global Health India.

Dimerix share price snapshot

With today's intraday gains factored in, the Dimerix share price is up 39% over the past 12 months. By comparison the All Ordinaries Index (ASX: XAO) gained 27% over that same period.

Dimerix shares are currently trading 2% higher than this time last month.

The post Dimerix (ASX:DXB) share price soars 9% on COVID-19 news appeared first on The Motley Fool Australia.

In fact, the market hasn't heard anything from Dimerix in more than a week.

Right now, Dimerix's shares are swapping hands for 35 cents apiece, 2.94% more than they were at yesterday's close.

Let's take a look at what might be boosting the drug development company's stock on Thursday.

What's boosting Dimerix's stock today?

The Dimerix share price has well and truly recovered from a major fall last week.

Last Tuesday, Dimerix released a prospectus for a share purchase plan, to the detriment of its share price. Under the prospectus, investors could purchase up to $30,000 worth of new Dimerix shares for 20 cents apiece.

The Dimerix share price plummeted 11.7% to 30 cents following the prospectus' release. Luckily, it bounced back quickly.

Perhaps Dimerix's recovery was aided by its announcement that it had begun its phase 3 clinical study in patients with focal segmental glomerulosclerosis (FSGS). The study is named ACTION3.

The company broke the news that it's filed the first ethics submission for the study last Wednesday. If the submission is approved, the company can begin recruiting patients.

The study is expected to run over 167 sites in 18 countries, with Australia and New Zealand set to be the first out of the gate.

Dimerix will be testing the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker.

The company expects to screen the first of the study's patients in the last quarter of 2021.

Dimerix share price snapshot

Today's gains have added to the strong recent performance of the Dimerix share price.

The company's shares are currently going for 45% more than they were at the start of 2021. However, they're still trading for 50% less than they were this time last year.

The post The Dimerix (ASX:DXB) share price is up 3% on Thursday appeared first on The Motley Fool Australia.